Bazemore Robert B — SEC insider filings
SEC reporting owner CIK 1620152. 24 insider filings on record with FilingPulse; latest filed 2026-10-16.
Transaction summary — filings shown
Covers all 24 filings on record, filed 2021-01-27 to 2026-10-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 1 leg across 1 filing — 5,000 shares, $49,900 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 3 legs across 3 filings — 20,287 shares, $193,929 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 37.
- Largest priced transaction: sale of 10,328 shares @ $7.85 ($81,075) in Epizyme, Inc., filed 2021-03-29.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Epizyme, Inc. (EPZM) | President & CEO, Director | 4 | — | 3 legs · 20,287 sh · $193,929 | 2 |
| Nuvation Bio Inc. (NUVB) | Director | 9 | 1 leg · 5,000 sh · $49,900 | — | 9 |
| Akari Therapeutics Plc (AKTX) | Director | 5 | — | — | 18 |
| ARDELYX, INC. (ARDX) | Director | 6 | — | — | 8 |
Insider filings — Bazemore Robert B
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-16 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 13,100 @ $7.90 · Grant/award (A): 4,677 @ $7.90 · Option exercise (M): 773 @ $0.00 · Option exercise (M): 3,093 @ $0.00 · Grant/award (A): 45,000 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 · +2 more | EDGAR |
| 2026-06-18 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 26,455 @ $0 · Grant/award (A): 39,715 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 123,397 (derivative) @ $0 | EDGAR |
| 2025-12-18 | 4 | Akari Therapeutics Plc (AKTX) | Purchase (P): 123,731 (derivative) · Purchase (P): 123,731 (derivative) @ $0.40 · Purchase (P): 30,932 (derivative) · Purchase (P): 30,932 (derivative) @ $0.40 | EDGAR |
| 2025-06-23 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 41,551 @ $0 · Grant/award (A): 54,059 (derivative) @ $0 | EDGAR |
| 2025-05-23 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 292,983 (derivative) @ $0 | EDGAR |
| 2025-03-24 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 175,000 (derivative) @ $0 · Grant/award (A): 225,000 (derivative) @ $0 | EDGAR |
| 2025-03-10 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 44,642 @ $1.12 · Grant/award (A): 44,642 (derivative) @ $1.12 · Grant/award (A): 44,642 (derivative) @ $1.12 | EDGAR |
| 2024-09-18 | 4 | Akari Therapeutics Plc (AKTX) | Grant/award (A): 5,000,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 200,801 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 40,243 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 49,237 (derivative) @ $0 | EDGAR |
| 2023-05-17 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 366,744 (derivative) @ $0 | EDGAR |
| 2022-06-28 | 4/A | Nuvation Bio Inc. (NUVB) | Grant/award (A): 140,713 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2022-05-18 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 118,784 (derivative) @ $0 | EDGAR |
| 2021-11-02 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 45,229 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | ARDELYX, INC. (ARDX) | Grant/award (A): 32,765 (derivative) @ $0 | EDGAR |
| 2021-04-01 | 4 | Nuvation Bio Inc. (NUVB) | Purchase (P): 5,000 @ $9.98 | EDGAR |
| 2021-03-29 | 4 | Epizyme, Inc. (EPZM) | Sale (S): 10,328 @ $7.85 | EDGAR |
| 2021-02-12 | 4 | Nuvation Bio Inc. (NUVB) | Grant/award (A): 51,703 (derivative) · Grant/award (A): 187,658 (derivative) | EDGAR |
| 2021-02-05 | 4 | Epizyme, Inc. (EPZM) | Sale (S): 3,890 @ $11.21 | EDGAR |
| 2021-02-02 | 4 | Epizyme, Inc. (EPZM) | Grant/award (A): 87,500 @ $0 · Grant/award (A): 417,443 (derivative) @ $0 | EDGAR |
| 2021-01-27 | 4 | Epizyme, Inc. (EPZM) | Sale (S): 6,069 @ $11.41 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1620152 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs